PK parameters explained: From Cmax to clearance (and why it matters for development decisions)
Learn how key PK parameters such as Cmax, AUC, clearance, half life, and volume of…
Sebastian Kuechenmeister2026 年 4 月 9 日
Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations
Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…
Certara2026 年 4 月 2 日
Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection
PK/PD Modeling for CNS drug development using Phoenix NLME and machine learning for better CNS…
Certara2026 年 3 月 26 日
Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis
This study evaluated the pharmacokinetics (PK) and pharmacokinetic–pharmacodynamic (PK–PD) relationship of clazakizumab, an anti–interleukin-6 (IL-6)…
Danielle Pillsbury2026 年 3 月 24 日
From Numbers to Narrative: Mastering the Art of PK Presentation
Master PK data reporting with a structured guide to presenting pharmacokinetic results clearly and turning…
Certara2026 年 3 月 20 日
Pharmacometrics Under Pressure
popPK modelers and pharmacometricians, ensure your toolset can handle use cases from translation to population.
Certara2026 年 3 月 20 日
What are common bioequivalence study mistakes?
Learn about the most common bioequivalence study mistakes drug developers make and the differences between…
Certara2026 年 3 月 20 日
